Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Deutsche Biotech Innovativ AG. (7/24/15). "Press Release: AGM Approves Bonus Shares and Capital Increase". Hennigsdorf.

Organisations Organisation Deutsche Biotech Innovativ AG (DBI AG)
  Group Deutsche Biotech Innovativ (Group)
  Organisation 2 Kirchhoff Consult AG
Products Product adrecizumab
  Product 2 DB1RA (Oncoprevent GmbH / DIB AG)
Index terms Index term Deutsche Biotech Innovativ–SEVERAL: investment, 201508–201511 capital increase €1.6m 49k new shares €33.5/share out of 596.4k shares on public offer
  Index term 2 Deutsche Biotech Innovativ–Kirchhoff Consult: public relations, 201508 service existent by Kirchhoff Consult AG
Person Person Wegener, Bernd (Deutsche Biotech Innovativ AG before BRAHMS CEO)
     


The Annual General Meeting of Deutsche Biotech Innovativ AG ("DBI"), which was held in Berlin yesterday, has approved all resolutions proposed by the Management Board and the Supervisory Board of the company with 100 percent. Overall, 98.91 percent of the share capital of the Company were represented.

In particular, the shareholders approved the issue of bonus shares by a capital increase from company funds in the ratio 1:1. Thus, by issuing 447,300 new shares the share capital of the Company will double from currently EUR 447,300.00 to EUR 894,600.00, divided into 894,600 no-par value bearer shares.

In addition, the Annual General Meeting resolved a capital increase against cash contributions by issuing up to 596,400 new shares. The subscription price will be determined later and the shares will be offered to the shareholders for a period of at least two weeks. Any shares not subscribed after the end of the subscription period may be offered to the shareholders and/or interested investors for subscription or purchase. The Management Board was authorized to determine with the approval of the Supervisory Board the further details of the capital increase. This capital increase is expected to be carried out in the second half of 2015.

With the funds generated from the capital increase DBI plans to advance its drug development. This includes in particular the execution of Phase I and II clinical trials with the "First-in-Class" sepsis drug Adrecizumab and the finalization of the pre-clinical studies for the drug DB1RA for prevention of breast cancer.

"We at DBI develop drugs for unmet medical needs. The funds from the capital increase shall allow us to build up and expand our drug pipeline in the future furthermore," says Dr. Bernd Wegener, CEO of DBI.


About Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG ("DBI") is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. The focus of the R&D is on drugs for sepsis and cancer. The company's main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a phase I study starting in 2015.

DBI aims to further expand its drug pipeline and invests in the research and development of drugs that possess a high unique selling point potential.

The members of the DBI Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have long-standing experience in the biotechnology field. Both were part of the founders' and management team of B.R.A.H.M.S. AG, a very successful biotechnology company specializing in the development of blood biomarker for diagnosis and therapy treatment of serious diseases, which was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).


For further information please contact:

Deutsche Biotech Innovativ AG
Susanne Wallace
Tel.: +49 (0)3302 20 77 811
E-mail: s.wallace@dbi-ag.de

Kirchhoff Consult AG
Anja Ben Lekhal
Tel.: +49 (0)40 609 186 55
E-mail: anja.benlekhal@kirchhoff.de

   
Record changed: 2017-04-02

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Deutsche Biotech Innovativ (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81




» top